For the better part of two years, Stockhouse has been covering the steady growth of the psychedelics market and how the mental health & wellness sector has benefited from the scientific and medical development of so-called magic mushrooms.’ Now, the investment community is beginning to drive capital markets in this space to heights few could’ve imagined even two years ago.

Psilocybin-assisted psychotherapy is currently being widely studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders.

Just over a year ago, Stockhouse covered an intriguing forum at the Extraordinary Future Conference in Vancouver, BC entitled: From the Plant Medicine Frontier - How Psychedelics like Psilocybin could upturn the mental health industry.” Keynote speaker and author, pioneering research pharmacognosist, lecturer, and one of the world’s leading authorities into the medicinal properties and mental health benefits of psychedelics, Dr. Dennis McKenna, had this to say:

Psychedelics are unlike any other kind of medicine that’s ever been introduced into biomedicine. Of all the new drugs discovered that eventually make it through clinical trials and eventually becomes available to people, these (psychedelic) drugs are not like them. They can’t be reduced to just another pill’ because they are connected with history and a cultural context and even a co-evolutionary aspect. No one wants to discourage the research on psychedelics and the development of high quality psychedelics for therapeutic uses, but should also not turn our backs on nature.”

Today, massive amounts of capital are entering the psychedelic health & wellness space. And the biggest splash was recently made by Compass Pathways PLC (NASDAQ: CMPS) a U.K. unicorn start-up backed by tech billionaire Peter Thiel and lead investor Christian Angermayer. Labelled as the industry’s most anticipated psychedelic IPO”, Compass became the first psychedelic medical company to go public on a major U.S. exchange. The drug-maker's shares promptly rose by an eye-popping 70% during their first day of trading on the Nasdaq. At press time, Compass Pathways’ market cap had ballooned to over $1.42 billion, making it the most valuable psychedelics company in the world.

Even celebrity businessmen like former Canopy Growth CEO Bruce Linton and Dragon’s Den and Shark Tank star Kevin O’Leary have gotten into psychedelics the game.

But where real value and opportunity often reside is in the domain of small capitalization companies. Now, savvy investors are looking at a number of aggressively positioned small caps that are moving rapidly to grab attention and gain traction within capital markets.

One such company is Numinus Wellness Inc. (NUMI) (TSX-V.NUMI, OTCMKTS: LKYSF, Forum) a relatively new player in the space that is advancing psychedelic laboratory testing, therapy, and research, and hope to create a lifelong relationship between the Company and its clientsa journey to heal and be well.”

NUMI’s unique ecosystem of health solutions is centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies to treat a myriad of mental health ailments, primarily depression and drug & alcohol addiction. The Company recently announced announce it has commenced cultivating psilocybin mushrooms at its 7000 square-foot Health Canada-licensed facility.

In a recent Stockhouse article, our investor audience was introduced to a soon-to-be-CSE-listed Company that’s advancing psychedelic and nutraceutical-based products. Cybin Corp. (P.CYBN, Forum) is launching psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, Cybin is structuring and supporting clinical studies across North America and other regions, through strategic academic and institutional partnerships.

Vancouver BC-based Universal Ibogaine Inc. (UI) (P.IBO, Forum) has a slightly different business model, currently focussed on addressing the opioid epidemic through proven plant medicine ibogaine. The Company operates franchise clinics with a safe and effective, seven-day treatment with ibogaine to deal with the opioid crisis, changing attitudes towards vibrant new medical solutions.

The detox treatment has been developed and tested by Cancun MX-based Clear Sky Recovery and has proven to be a superior alternative to standard treatments, pharmaceuticals, natural medicines, and recovery centreswith success rates estimated between 45 to 60%. With standard treatment centres achieving a typical recovery rate of about 4%, the ibogaine / Clear Sky Recovery method has demonstrated a ten-fold improvement over traditional treatment programs.

With its corporate motto, from Underground to Mainstream” Red Light Holland Corp. (TRIP) (CSE: TRIP, OTC: ACPQF, Forum) has carved out its niche in the magic truffle’ business. With a distinctly different business model from aforementioned treatment-based psychedelics companies, TRIP is now positioned to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands.”

In addition, Red Light Holland recently reached several distribution arrangements for their iMicrodose packs which will be sold in several locations around the Netherlands for adult usage. Todd Shapiro, CEO and Director of Red Light Holland is very proud to be able to say that they are selling the first legal psilocybin product in the world and he looks forward to reaching new markets in the future, which he doesn’t think is too far off.

The Company is currently growing three different strains of magic truffles and expects to have an initial batch of approximately 100,000 grams of magic truffles available in late October 2020.

Stockhouse investors are gaining increasing insight into the scientific and medical marvels that psychedelic treatment can effectively provide people suffering from a wide variety of debilitating mental health issues, along with drug dependency and abuse.

Stay tuned to Stockhouse in the upcoming months for continuing news updates and investors alerts surrounding the burgeoning psilocybin / psychedelics marketplace.

FULL DISCLOSURE: Red Light Holland Corp., Numinus Wellness Inc., Cybin Corp. and Universal Ibogaine Inc. are clients of Stockhouse Publishing.

Here is the original post:

Opening the Door to the New Psychedelics Revolution | 2020-10-09 | Investing News - Stockhouse